Georgetown Lombardi Comprehensive Cancer Center | Strategic Alliance Partners

Latest from Georgetown Lombardi Comprehensive Cancer Center


Luminary Awards Honor GI Experts, Patient Advocate

November 18, 2022

OncLive® and The Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center, have recognized 4 gastrointestinal physician-scientists and a prominent patient advocate, naming them as 2022 Luminary Awards in GI Cancers.

Marshall Provides Insight on Evolving Treatment Patterns in ESCC

October 13, 2022

John L. Marshall, MD, provides an overview of esophageal squamous cell carcinoma and discusses several key updates to the treatment landscape, including putting data in the context of the treatment algorithm.

Dual Checkpoint Blockade Holds Promise as Long-term Treatment Option in NSCLC

August 19, 2022

Stephen V. Liu, MD and Neal E. Ready, MD, PhD, discuss the new data with nivolumab plus ipilimumab in treatment-naïve NSCLC and provide commentary on treatment considerations for patients who are eligible to receive these regimens.

Durvalumab Plus Chemotherapy Maintains OS Benefit in Advanced Biliary Tract Cancer

June 30, 2022

The addition of durvalumab to gemcitabine and cisplatin demonstrated an improvement in overall survival vs gemcitabine and cisplatin plus placebo as frontline therapy in patients with advanced biliary tract cancer, regardless of primary tumor location.

Gibney Breaks Down the Evolving Treatment Landscape of Melanoma

June 15, 2022

Geoffrey T. Gibney, MD, discusses current treatment options for patients with melanoma, clinical trials that have explored different agents and combinations, and developing treatment options in uveal melanoma.

Afatinib Efficacy and Safety to Be Investigated in Metastatic Solid Tumors With NRG1 Fusions

June 07, 2022

Afatinib may prove effective and tolerable in patients with advanced or metastatic solid tumors with NRG1 gene fusions, according to the rationale for a prospective real-world outcomes study that was presented as a trial in progress at the 2022 ASCO Annual Meeting.

Trastuzumab Deruxtecan Represents Potential New Second-Line Standard in HER2+ Metastatic Gastric/GEJ Cancer

October 20, 2021

John Marshall, MD, discusses the results of the DESTINY-Gastric02 trial with trastuzumab deruxtecan in patients with HER2-positive gastric/GEJ cancer, the importance of molecular profiling, and future considerations for the antibody-drug conjugate.

The Marshalls Open a Candid Conversation About Cancer

April 01, 2021

The Marshalls go beyond the pages of their new memoir, Off Our Chests: A Candid Tour Through the World of Cancer, to discuss how Liza's diagnosis of triple-negative breast cancer changed their lives and the key messages they hope readers will take from their book.